Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer.

Autor: Paik, E Sun1, Kim, Tae-Hyun2, Cho, Young Jae3, Ryu, Jiyoon3, Choi, Jung-Joo3, Lee, Yoo-Young3, Kim, Tae-Joong3, Choi, Chel-Hun3, Kim, Woo Young1, Sa, Jason K.4, Lee, Jin-Ku5, Kim, Byoung-Gie3, Bae, Duk-Soo3, Han, Hee Dong6, Ahn, Hyung Jun7, Lee, Jeong-Won3,8,9 garden.lee@samsung.com
Zdroj: Scientific Reports. 3/17/2020, Vol. 10 Issue 1, p1-9. 9p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje